NVO Gets Positive CHMP Opinion for Wegovy's Label Update in EU
Novo Nordisk A/S NVO announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) adopted a positive opinion, recommending a label update of its blockbuster weekly injection for chronic weight management,
Novo Nordisk's Wegovy Recommended For Label Update To Reflect Heart Failure Benefits
Novo Nordisk said that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a
European Drug Agency Supports Novo Nordisk's Blockbuster Weight-Loss Drug Wegovy For Obesity-Related Heart Failure
Novo Nordisk's Wegovy label update receives a positive opinion from the EMA's CHMP, highlighting improvements in heart failure symptoms, physical limitations, and exercise function in patients with obesity-related HFpEF.
EMA CHMP recommends label update to Novo Nordisk’s Wegovy
The European Medicines Agency's Committee for Medicinal Products for Human Use has recommended an update to Novo Nordisk’s Wegovy label.
EMA committee recommends Novo Nordisk’s Wegovy label update to reflect reduced heart failure symptoms and improved physical function
Bagsværd, Denmark Saturday, September 21, 2024, 15:00 Hrs [IST]
Novo Nordisk’s Wegovy Gets EU Backing to Treat Obesity-Related Heart Failure
Novo Nordisk said European regulators support the use of its blockbuster weight-loss drug Wegovy to help reduce heart failure in obese patients.
Yahoo Finance22d
Novo Nordisk Touts Encouraging Wegovy Data To Lower Risk Of Severe Complications In Heart Failure Patients
STEP-HFpEF, and STEP-HFpEF DM trials. According to the analysis, semaglutide led to a 31% reduced risk of combined cardiovascular (CV) death or worsening heart failure (HF) events, based on an ...
PipelineReview.com1d
Wegovy® recommended by the European regulatory authorities for label update to reflect reduced heart failure symptoms and improved physical function
BAGSVAERD, Denmark I 19, 2024 I Novo Nordisk today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human ...
The American Journal of Managed Care22d
Semaglutide Enhances Heart Failure Outcomes in Obesity
Semaglutide and Atrial Fibrillation A subanalysis of data from the STEP-HFpEF and STEP-HFpEF DM trials 5 showed that patients with aFib—45% of the STEP-HFpEF program population—have ...
pharmaphorum19d
Semaglutide scores again, this time in heart failure
Novo Nordisk has just released the results of the phase 3 STEP-HFpEF trial showing that semaglutide was able to reduce symptoms and improve exercise capacity in overweight people with heart ...